Earnings ·
GH Research reports $15.1M net loss in Q2 2026 as R&D expenses rise to $24.8 million
GHRSGH Research PLC
GH Research PLC reported second quarter 2026 financial results on August 6, 2026. The company incurred a net loss of $15.1 million, or $0.23 per share, compared to a $9.3 million loss in the prior year period. For the six months ended June 30, 2026, total R&D expenses rose to $24.8 million from $16.8 million, driven by increased clinical development costs for its mebufotenin therapies. The company holds $362.7 million in cash and marketable securities as of June 30, 2026, following an underwritten equity offering in April that generated $111.2 million in net proceeds. Operationally, GH Research completed Phase 1 trials for its proprietary aerosol delivery device (GH001-HV-106) and its IND-opening trial in the US (GH001-HV-109). In July 2026, the FDA confirmed that CMC and device plans appear Phase 3 ready, with the company targeting pivotal program initiation later this year. Additionally, the U.S. Patent and Trademark Office granted a new patent for mebufotenin aerosol methods expiring no earlier than 2043, and the European Patent Office maintained key opposition claims. GH Research PLC is a clinical-stage biopharmaceutical company developing mebufotenin therapies for treatment-resistant depression.